Medizintechnik Purchases BSD Medical's BSD-2000/3D/MR Hyperthermia System

SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that Dr. Sennewald Medizintechnik GmbH (Medizintechnik) has purchased BSD Medical's BSD-2000/3D/MR Hyperthermia System (BSD-2000/3D/MR). This BSD-2000/3D/MR system is an integration of BSD‘s advanced regional hyperthermia system with a Magnetic Resonance (MR) Imaging System from Siemens Healthcare. This BSD-2000/3D/MR System is equipped with an innovative array of MR compatible applicators: the Sigma Eye MR applicator for the treatment of adults, the Sigma 40 MR applicator for the treatment of small adults and older children, and the Sigma 30 MR applicator for the treatment of younger children down to the age of 3.

The BSD-2000/3D/MR is an integration of the world’s most sophisticated hyperthermia therapy system with magnetic resonance imaging. It introduces a revolutionary new use of magnetic resonance imaging, expanding MRI utilization from its traditional role in diagnostic imaging to real-time imaging and monitoring of cancer treatments. The magnetic resonance images are color graded to show temperature changes in the treatment area during hyperthermia therapy. The BSD-2000/3D/MR System was developed in a collaborative effort with Siemens Healthcare AG, Erlangen, Germany. The BSD-2000/3D/MR has received CE Marking approval.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. The BSD-2000 is restricted to investigational use in the US. BSD has applied for a Humanitarian Device Exemption (HDE) approval for its BSD-2000 Hyperthermia System and this submission is currently under review by the FDA. For further information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.